On-and-off approach to prostate cancer treatment may compromise survival

Large, international trial finds intermittent androgen deprivation is not equivalent to continuous treatment

2013-04-04

(Press-News.org) ANN ARBOR, Mich. — Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.

Based on previous smaller studies, it looked like an approach called intermittent androgen deprivation therapy might be just as good as continuous androgen deprivation in terms of survival while meanwhile giving patients a breather from the side effects of therapy. In fact, researchers believed intermittent therapy might help overcome treatment resistance that occurs in most patients with metastatic hormone-sensitive prostate cancer.

But this new study, which treated 1,535 patients with metastatic prostate cancer and followed them for a median of 10 years, finds that's not the case. Results appear in the New England Journal of Medicine.

"We tried to see whether intermittent androgen deprivation is as good as continuous androgen deprivation, but we did not prove that. We found that intermittent therapy is certainly not better and moreover we cannot even call it comparable," says lead study author Maha Hussain, M.D., FACP, a prostate cancer expert oncologist at the University of Michigan Comprehensive Cancer Center.

The study was sponsored by SWOG, a National Cancer Institute-supported cancer clinical trials cooperative group.

In the study, men with metastatic hormone-sensitive prostate cancer were given an initial course of androgen deprivation therapy (hormone therapy), which is standard therapy for this disease. Patients with a stable or declining PSA level equal to or below a cut-off of 4 ng/ml were then randomly assigned either to continue or to discontinue the hormone therapy. Patients were carefully monitored with monthly PSAs and a doctor's evaluation every three months and therapy was resumed in the intermittent arm when PSA climbed to 20 ng/ml. The intermittent cycle continued on-and-off based on the PSA levels.

Survival among the two groups showed a 10 percent relative increase in the risk of death with intermittent therapy, with average survival of 5.8 years for the continuous group and 5.1 years for the intermittent group from the time of randomization.

Further, the researchers looked at quality of life between the two groups of patients. Initially the intermittent therapy group showed significant improvement in impotence and emotional function in the first three months and had improved trends in other aspects of quality of life compared to the continuous group. But these differences leveled off over time.

"The improvements in some aspects of quality of life that were observed early were not sustained after a few months as patients had to resume therapy," says Hussain professor of internal medicine and urology at the U-M Medical School.

"If a patient is coming in with newly metastatic prostate cancer, hormone treatment continuously is the standard. If they wish to do intermittent treatment, they should be counseled that based on this data, their outcome might be compromised," she adds.

INFORMATION:

Follow-up studies are investigating a new generation of anti-hormone treatments combined with current therapies in the hopes of increasing the treatment's effectiveness. For information about currently available clinical trials at U-M, call the Cancer AnswerLine at 800-865-1125.

Prostate cancer statistics: 238,590 Americans will be diagnosed with prostate cancer this year and 29,720 will die from the disease, according to the American Cancer Society

Additional authors: Catherine M. Tangen, Dr.P.H., SWOG Statistical Center; Donna L. Berry, Ph.D., R.N., Dana-Farber Cancer Institute; Celestia S. Higano, M.D., University of Washington; E. David Crawford, M.D., University of Colorado Health Science Center; Glenn Liu, M.D., and George Wilding, M.D., University of Wisconsin Carbone Cancer Center; Stephen Prescott, M.D., St. James's University Hospital (UK); Subramanian Kanaga Sundaram, M.D., The Mid Yorkshire Hospitals-Pinderfields Hospital (UK); Eric Jay Small, M.D., University of California, San Francisco; Nancy Ann Dawson, M.D., Georgetown University Hospital Lombardi Comprehensive Cancer Center; Bryan J. Donnelly, M.D., Prostate Cancer Centre (Canada); Peter M. Venner, M.D., Cross Cancer Institute (Canada); Ulka N. Vaishampayan, M.D., Karmanos Cancer Institute; Paul F. Schellhammer, M.D., Urology of Virginia; David I. Quinn, M.D., Ph.D., University of Southern California Norris Comprehensive Cancer Center; Derek Raghavan, M.D., Ph.D., Levine Cancer Institutes; Benjamin Ely, M.S., SWOG Statistical Center; Carol M. Moinpour, Ph.D., Fred Hutchinson Cancer Research Center; Nicholas J. Vogelzang, M.D., US Oncology Research, LLC, McKesson Specialty Health, Comprehensive Cancer Centers of Nevada; Ian M. Thompson Jr., M.D., University of Texas Health Science Center

Funding: National Cancer Institute grants CA32102, CA38926, CA14028, CA55582, CA42777, CA35192, CA46441, CA46282, CA27057, CA128567, CA45807, CA20319, CA58416, CA46113, CA04919, CA76132, CA58861, CA58686, CA68183, CA12644, CA35261, CA35431, CA46368, CA22433, CA63848, CA67575, CA76447, CA67663, CA46136, CA86780, CA35281, CA63844, CA45560, CA37981, CA11083, CA35178, CA95860, CA35176, CA21115, CA31949, CA77202, CCSRI 015469; Astra Zeneca; Fonds Cancer (FOCA) from Belgium

Disclosure: None

Reference: New England Journal of Medicine, Vol. 368, No. 14, April 4, 2013

Resources:

U-M Cancer AnswerLine, 800-865-1125

U-M Comprehensive Cancer Center, http://www.mcancer.org

Clinical trials at U-M, http://www.UMClinicalStudies.org/cancer

ELSE PRESS RELEASES FROM THIS DATE:

Researchers find potential map to more effective HIV vaccine

2013-04-04

DURHAM, NC – By tracking the very earliest days of one person's robust immune response to HIV, researchers have charted a new route for developing a long-sought vaccine that could boost the body's ability to neutralize the virus. The research team, led by Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute, and John Mascola, M.D., acting director of the NIH Vaccine Research Center, have for the first time described the co-evolution of antibodies and virus in a person with HIV whose immune system mounted a broad attack against the pathogen. Findings are ...

Thin clouds drove Greenland's record-breaking 2012 ice melt

2013-04-04

MADISON — If the sheet of ice covering Greenland were to melt in its entirety tomorrow, global sea levels would rise by 24 feet. Three million cubic kilometers of ice won't wash into the ocean overnight, but researchers have been tracking increasing melt rates since at least 1979. Last summer, however, the melt was so large that similar events show up in ice core records only once every 150 years or so over the last four millennia. "In July 2012, a historically rare period of extended surface melting raised questions about the frequency and extent of such events," says ...

Brain cell signal network genes linked to schizophrenia risk in families

2013-04-04

New genetic factors predisposing to schizophrenia have been uncovered in five families with several affected relatives. The psychiatric disorder can disrupt thinking, feeling, and acting, and blur the border between reality and imagination. Dr. Debby W. Tsuang, professor of psychiatry and behavioral sciences, and Dr. Marshall S. Horwitz, professor of pathology, both at the University of Washington in Seattle, led the multi-institutional study. Tsuang is also a staff physician at the Puget Sound Veterans Administration Health Care System. The results are published in ...

Satellite tagging maps the secret migration of white sharks

2013-04-04

Long-life batteries and satellite tagging have been used to fill in the blanks of female white sharks' (Carcharodon carcharias) lifestyles. Research published in the launch edition of BioMed Central's open access journal Animal Biotelemetry defines a two year migratory pattern in the Pacific Ocean. Pregnant females travel between the mating area at Guadalupe Island and nursery in Baja California, putting them and their young at risk from commercial fishing. White sharks are pelagic much of their time, living in the open ocean. However they are also philopatric, in that ...

A fingerprint of exhaled breath

2013-04-04

Bodily fluids contain lots of information about the health status of a person. Medical doctors routinely have blood and urine analysed in order to obtain hints for infectious and metabolic diseases, to diagnose cancer and organ failure, and to check the dose of medication, based on compounds present in these body fluids. Researchers at ETH Zurich and at the University Hospital Zurich now propose to extend such analyses to breath, and in particular to take advantage of modern high-resolution analytical methods that can provide real-time information on the chemical composition ...

Baldness linked to increased risk of coronary heart disease

2013-04-04

Male pattern baldness is linked to an increased risk of coronary heart disease, but only if it's on the top/crown of the head, rather than at the front, finds an analysis of published evidence in the online journal BMJ Open. A receding hairline is not linked to an increased risk, the analysis indicates. The researchers trawled the Medline and the Cochrane Library databases for research published on male pattern baldness and coronary heart disease, and came up with 850 possible studies, published between 1950 and 2012. But only six satisfied all the eligibility criteria ...

Low testosterone levels may herald rheumatoid arthritis in men

2013-04-04

Low testosterone levels may herald the subsequent development of rheumatoid arthritis in men, suggests research published online in the Annals of the Rheumatic Diseases. Sex hormones are thought to play a part in the development of rheumatoid arthritis, and both men and women with the condition tend to have lower levels of testosterone in their blood than healthy people. But it is not clear whether this is a contributory factor or a consequence of the disease. The researchers based their findings on participants of the Swedish Malmo Preventive Medicine Program (MPMP), ...

NIH scientists, grantees map possible path to an HIV vaccine

2013-04-04

In an advance for HIV vaccine research, scientists have for the first time determined how both the virus and a resulting strong antibody response co-evolved in one HIV-infected individual. The findings could help researchers identify which proteins to use in investigational vaccines to induce antibodies capable of preventing infection from an array of HIV strains. Previously, a study of antibody genetics enabled scientists to deduce the step-by-step evolution of certain broadly neutralizing antibodies—those that can prevent infection by the majority of HIV strains found ...

Shark tooth weapons reveal missing shark species in Central Pacific islands

2013-04-04

The Gilbert Island reefs in the Central Pacific were once home to two species of sharks not previously reported in historic records or contemporary studies. The species were discovered in a new analysis of weapons made from shark teeth and used by 19th century islanders, reported in a study published April 3 in the open access journal PLOS ONE by Joshua Drew from Columbia University and colleagues from the Field Museum of Natural History. Sharks were culturally important to the Gilbertese Islanders; historic records indicate a complex ritual system surrounding shark fishing ...

NIH scientists develop monkey model to study novel coronavirus infection

2013-04-04

WHAT: National Institutes of Health (NIH) researchers have developed a model of infection in rhesus macaques that will help scientists around the world better understand how an emerging coronavirus, first identified in September 2012, affects people. The virus has so far infected at least 17 people in the Middle East and Europe, killing 11 of them. The NIH team established the nonhuman primate model in December 2012 and is using it to study how the virus causes disease and to evaluate potential vaccines and antiviral treatments. The model shows that clinical signs ...

On-and-off approach to prostate cancer treatment may compromise survival

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: